Key facts today
Novo Nordisk's stock has declined due to increased competition and poor trial results for CagriSema. The FDA's move to address Semaglutide shortages may strengthen its market position.
Novo Nordisk's NovoCare Pharmacy program allows self-paying patients to access Wegovy for $499. Eligible customers can access a bundled offer starting at $599 monthly for all doses.
Novo Nordisk (NOVO_B) experienced a 3.2% increase in its stock price during trading on Tuesday, aligning with the overall rise of European equities traded in the US.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
65.43 MXN
291.41 B MXN
837.97 B MXN
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG01292CB20
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NVO Novo Nordisk: $195 | The Cure since forever it addresses on major conditions of humans
Diabetes Cardio Alzheimer's
from acquisition to partnering and continuous r&d
this issue is a model to new science and tech companies making it to the next 50 years
key is innovation
opportunity is wait for major crash to upsize for OG investors
or s
Novo Nordisk's The recent drop in Novo Nordisk's stock price is attributed to several factors. A key issue is the company’s struggle to meet the surging demand for its weight-loss drugs, such as Wegovy. Although demand remains strong, investors are concerned about Novo Nordisk's ability to scale up production and
NVO absolutely sweet levelThis downturn is attributed to disappointing clinical trial results for some of its drugs and concerns over potential tariffs affecting Denmark. Additionally, competition from Eli Lilly's successful weight-loss drug trials has impacted investor confidence.
Despite these challenges, analysts note
$NVO offers solid risk to reward for long term buyers! - I had previously called out that NYSE:NVO would have more pain to come when it was in $85-90s I have attached the link with this post for my reader's reference.
- Now, I am turning bullish on this name given these prices and compressed multiples for the growth prospects it offers.
Fundamenta
NVO: Oversold, But I’m Staying PatientYes, NVO has pulled back hard — from highs near $148 to the mid-$60s, now trading around $68.33. While this selloff may look oversold on many levels, I’m still avoiding the stock for now.
The broader market remains in a downtrend, and with macro uncertainty still front and center, I’m not eager to
NVO, Rhyming with historical golden buy zoneUsing the Guassian Channel indicator on the monthly timeframe. We can see that in the past, after the price has significantly correct from its ATH of 50%+, price tend to reverse at the lower channel support(2times on chart) or at the upper support line ( 1 time on the chart)
Right now we are curre
3/27/25 - $nvo - obvious at $70... 10% size3/27/25 :: VROCKSTAR :: NYSE:NVO
obvious at $70... 10% size
- at btc conf in miami so have been hoping for a quiet week. well. whatever. another day in trumptopia. but alas, we can't tell the market what we want. so the game today is just don't make big mistakes and try and find interesting asymm
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOVOB/N is featured.
Related stocks
Frequently Asked Questions
The current price of NOVOB/N is 1,277.00 MXN — it hasn't changed in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange NOVO NORDISK A/S stocks are traded under the ticker NOVOB/N.
NOVOB/N stock hasn't changed in a week, the month change is a −15.82% fall, over the last year NOVO NORDISK A/S has showed a −40.62% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOVOB/N price has a max estimate of 2,991.71 MXN and a min estimate of 1,047.10 MXN. Watch NOVOB/N chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOVOB/N reached its all-time high on Jun 14, 2024 with the price of 2,708.33 MXN, and its all-time low was 948.02 MXN and was reached on Jan 24, 2022. View more price dynamics on NOVOB/N chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NOVOB/N stock is 0.00% volatile and has beta coefficient of 1.42. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 5.50 T, it has decreased by −5.01% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVOB/N earnings for the last quarter are 18.29 MXN per share, whereas the estimation was 17.25 MXN resulting in a 6.08% surprise. The estimated earnings for the next quarter are 18.13 MXN per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 247.24 B MXN, despite the estimated figure of 231.24 B MXN. In the next quarter, revenue is expected to reach 231.74 B MXN.
NOVOB/N net income for the last quarter is 81.46 B MXN, while the quarter before that showed 80.28 B MXN of net income which accounts for 1.47% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 29, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 431.53 B MXN, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOVOB/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the strong sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.